These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33288628)

  • 1. Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models.
    Moquist PN; Bovee TD; Waight AB; Mitchell JA; Miyamoto JB; Mason ML; Emmerton KK; Stevens N; Balasubramanian C; Simmons JK; Lyon RP; Senter PD; Doronina SO
    Mol Cancer Ther; 2021 Feb; 20(2):320-328. PubMed ID: 33288628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
    Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
    Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
    Akaiwa M; Dugal-Tessier J; Mendelsohn BA
    Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells and Mouse Models.
    Burns KE; Hensley H; Robinson MK; Thévenin D
    Mol Pharm; 2017 Feb; 14(2):415-422. PubMed ID: 28048942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable
    Sokka IK; Imlimthan S; Sarparanta M; Maaheimo H; Johansson MP; Ekholm FS
    Mol Pharm; 2021 Aug; 18(8):3125-3131. PubMed ID: 34296616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of Azastatin as a Potential ADC Payload with Reduced Bystander Killing.
    Hartmann RW; Fahrner R; Shevshenko D; Fyrknäs M; Larsson R; Lehmann F; Odell LR
    ChemMedChem; 2020 Dec; 15(24):2500-2512. PubMed ID: 33063934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
    Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
    J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling.
    Johansson MP; Maaheimo H; Ekholm FS
    Sci Rep; 2017 Nov; 7(1):15920. PubMed ID: 29162861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates.
    Maderna A; Leverett CA
    Mol Pharm; 2015 Jun; 12(6):1798-812. PubMed ID: 25697404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
    Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
    Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.
    Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G
    J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics.
    Waight AB; Bargsten K; Doronina S; Steinmetz MO; Sussman D; Prota AE
    PLoS One; 2016; 11(8):e0160890. PubMed ID: 27518442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer.
    Powell Gray B; Kelly L; Ahrens DP; Barry AP; Kratschmer C; Levy M; Sullenger BA
    Proc Natl Acad Sci U S A; 2018 May; 115(18):4761-4766. PubMed ID: 29666232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Anti-CD22-
    Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
    Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.